Bright Future Outlook and Huge Challenges to Overcome: An Attempt to Write the Short Story of the Biopharma Industry with Current Status, Selected Issues, and Potential Solutions in Discovery, R&D, and Manufacturing

Modern Biopharmaceuticals: Recent Success Stories

Volumn , Issue , 2013, Pages 487-526

  Jagschies, Günter ^a  

^a GE Healthcare Life Sciences   (Sweden)

Author keywords

Biomarker; Biopharma industry; Biopharmaceutical; Chromatography, downstream processing; Engineering firm; Manufacturing cost; Process development; Process integration; QbD; R D cost; Sourcing; Upstream processing

Indexed keywords

EID: 84885497662     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527669417.ch22     Document Type: Chapter

References (50)

1. DiMasi, J.A. and Grabowski, H.G. (2007) The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ., 28, 469-479.
2. [2008(] Harris Interactive: poll conducted online by between April 30 and May 14 2008, published by International Herald Tribune, May
3. Price Waterhouse Cooper (PWC) report: (2007) Pharma 2020, The Vision from http://www.pwc.com/extweb/ pwcpublications.nsf/docid/ 91BF330647FFA402852572F2005ECC22.
4. Walsh, G. (2005) Current status of modern biopharmaceuticals: Approved products and trends in approvals, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 1 (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1-34.
5. Wurm, F. (2005) Manufacture of recombinant Biopharmaceuticals, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 723-759.
6. Andersen, A.S. and Diers, I. (2005) Advanced expression of biopharmaceuticals at industrial scale: the insulin success story, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1033-1042.
7. Moscho, A., Schafer, M. A., and Yarema, K. (2005) Healthcare trends and their impact on the biopharmaceutical industry: biopharmaceuticals come of age, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VIII (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1711-1739.
8. Gutjahr, T. (2005) The development of Herceptin1: paving the way for individualized cancer therapy, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 1, part I (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 127-149.
9. Hempel, J.C. et al. (2005) Contract manufacturing of biopharmaceuticals including antibodies or antibody fragments, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1083-1142.
10. Moroney, S. and Pluckthun, A. (2005) Modern antibody technology: the impact on drug development, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part V (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1147-1186.
11. Gottschalk, U. and Mundt, K. (2005) Thirty years of monoclonal antibodies: a long way to pharmaceutical and commercial success, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part V (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1105-1145.
12. V́azquez, F.L. and Oya, R. (2005) AIDS gene therapy: a vector selectively able to destroy latently HIV-1-infectedCells, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 2, part II (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 549-559.
13. Boese, Q. and Khvorova, A., (2005) Rational siRNA design for RNA interference: optimization for therapeutic use, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 1, part I (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 243-264.
14. Morris, K.V. and Rossi, J.J. (2005) Combinatorial RNA-based Therapies for HIV-1, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 2, part II (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 569-577.
15. Kogure, K., Akita, H., Kamiya, H., and Harashima, H. (2005) Programmed packaging: a new drug delivery system and its application to Gene therapy, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VI (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1521-1534.
16. Lingnau, K., Klade, C., Buschle, M., and von Gabain, A. (2005) Novel vaccine adjuvants based on cationic peptide delivery systems, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VII (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1419- 1440.
17. Silacci, M. and Neri, D. (2005) Ligand-based targeting of disease: From antibodies to small organic (synthetic) ligands, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part V (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1271-1289.
18. Reissig, E., Graf, H., and Kapp, F.-J., (2005) Spheramine1: a cell therapeutic approach to Parkinson's disease, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 1, part I (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 325-348.
19. Modi, P., (2005) The evolving role of oral spray insulin in the treatment of diabetes, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VI (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1445-1460.
20. US Department of Health and Human Services, FDA (2004) Challenge and Opportunity on the Critical Path to New Medical Products, March
21. Hagel, L., Jagschies, G., and Sofer, G. (2007) Chapter 8: Process Economy in Handbook of Process Chromatography, 2nd edn, Elsevier Academic Press, pp. 189-218.
22. European Commission (2009) DG Competition Pharmaceutical Sector Inquiry, Final report, Adoption date: 8. July 2009, accessible at http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/communication_en.pdf
23. IBM Global Business Services Pharma 2010, The Threshold of Innovation, Somers, NY, 2004 from http://www-935.ibm.com/services/de/bcs/pdf/2006/pharma_2010.pdf (accessed 27 December, 2012).
24. Brorson, K. et al. (2005) Consideration for developing biopharmaceuticals: FDA perspective, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VII (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1637- 1667.
25. Wenzel, A.F. and Sonnega, C.E.A. (2005) The regulatory environment for biopharmaceuticals in the EU, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 4, part VII (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1669- 1701.
26. Geistlinger, J. and Ahnert, P. (2005) Large-scale detection of genetic variation: the key to personalized medicine, in Modern Biopharmaceuticals - Design, Development and Optimization, part I (ed. J. Knablein), Wiley-VCH Verlag GmbH, vol. 1, p. 71-93.
27. Huang, S .-M. an d Les ko, L. (2 005) The role of pharmacogenetics and pharmacongenomics, Modern Biop ha rmaceuticals - De s i gn, D ev e lo p me n t a nd Optimization, vol. 1, part I (ed. J. Knablein), Wi le y-V CH Ve r la g G mbH, p. 50-64.
28. Baker, M. (2005) In biomarkers we trust?, Nat. Biotechnol., 23 (3), 297-304.
29. IBM Global Business Services (2007) The evolving role of biomarkers, Somers, NY
30. US FDA (2004) Pharmaceutical cGMPsfor the 21st century -a risk-based approach, Final Report, September. accessible at http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ Manufacturing/Questionsand AnswersonCurrentGoodManufacturing PracticescGMPforDrugs/UCM176374.pdf.
31. US FDA (2006) Guidance for Industry, Q8 Pharmaceutical Development, May
32. US FDA (2008) ICH Draft Guidance: Q8 (R1) Pharmaceutical Development Revision 1, Jan
33. Rathore, A.S., Branning, R., and Cecchini, D. (2007) Quality: design space for biotech products. BioPharm, 20 (4).
34. Coffman, J.L., Kramarczyk, J.F., and Kelley, B.D. (2008) High-throughput screening of chromatographic separations: I. method development and column modeling. Biotechnol. Bioeng., 100 (4), 605-618.
35. Kelley, B.D., Switzer, M., Bastek, P., Kramarczyk, J.F., Molnar, K., Yu, T., and Coffman, J. (2008) High-throughput screening of chromatographic separations: IV. Ion-exchange. Biotechnol. Bioeng., 100 (5), 950-963.
36. Stokelman, A. (2007) Utilizing an advanced high-throughput microbioreactor experimentation system. Presented at PDA: Emerging Manufacturing and Quality Control Technologies, San Diego CA, January 2007.
37. Hagel, L., Jagschies, G., and Sofer, G. (2007) Chapter 2: Process capability in Handbook of Process Chromatography, 2nd edn, Elsevier Academic Press, pp. 23-39.
38. Reddy, P. (2007) Impact and benefits of applying QbD in cell line development to downstream process development. Presented at IBC Bioprocess International, Boston MA, October 1.
39. Riedel, N. and Dorner, F. (2005) A new technology standard for safety and efficacy in factor VIII replacement therapy: designing an advanced category rFVIII concentrate, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 2, part II (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 419-447.
40. Rose, T.,Winkler, K., Brundke, E., et al. (2005) Alternative strategies and new cell lines for high-level production of biopharmaceuticals, in Modern Biopharmaceuticals - Design,Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH VerlagGmbH, p. 761-776.
41. Yallop, C., Crowley, J., Cote, J., Hegmans-Brouwer, K., Lagerwerf, F., Gagne, R., Martin, J.C., Oosterhuis, N., Opstelten, D.-J., and Bout, A. (2005) PER. C61 cells for the manufacture of biopharmaceutical proteins, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 780-803.
42. Birch, J.R., Mainwaring, D.O., and Racher, A.J., Use of the glutamine synthetase (GS) expression system for the rapid development of highly productive mammalian cell processes, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 809-830.
43. Trexler-Schmidt, M. (2008) Platform facility fit issues for high titer processes. Presented at IBC Bioprocess International, Anaheim, CA, September 26.
44. Gadam, S. (2008) Reconfiguration of a commercial biologics facility to a launch facility for new product introductions: balancing process and engineering solutions. Presented at IBC Bioprocess International, Anaheim, CA, Septermber 26.
45. Kelley, B. (2007) Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol. Prog., 23, 995-1008.
46. Apeler, H. (2005) Producing modern biopharmaceuticals, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 1021-1031.
47. Gorr, G. and Wagner, S. (2005) Humanized glycosylation: production of biopharmaceuticals in a moss bioreactor, in Modern Biopharmaceuticals - Design, Development and Optimization, vol. 3, part IV (ed. J. Knablein), Wiley-VCH Verlag GmbH, p. 919-927.
48. Coffman, J.L., Bolton, G., Gallo, C., Tobler, S., and Godavarti, R. (2008) Technology development for purification of 1g/L/day antibody processes. Presented at Recovery of Biological Products, XIII, Quebec City, Canada, June 24.
49. Yang, P. (2009) Raising the bar in the biopharmaceutical industry: how effective leadership and innovation can help you become a best in class biopharmaceutical enterprise and maintain profitability in uncertain times. Presented at Biomanufacturing Summit '09, La Jolla, CA, January 26.
50. Farid, S.S. (2006) Established bioprocesses for producing antibodies as a basis for future planning. Adv. Biochem. Engin/Biotechnol., Springer Verlag Berlin, Heidelberg, published online 8 June.